- Volunteers who have undergone the phase II trial in May have shown positive early results, developing antibodies against the virus
(Karachi) Coronavirus vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said on Thursday.
The news comes as Moderna Inc, which is at the forefront of the country’s vaccine development efforts, reiterated earlier in the day that a late-stage trial with 30,000 volunteers would begin this month.
“We may be able to at least know whether we are dealing with a safe and effective vaccine by the early winter, late winter, (or) beginning of 2021,” Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, said in an interview to JAMA Network.
According to the firm, volunteers who have undergone the phase II trial in May have shown positive early results, developing antibodies against the virus.
In June, China National Biotec Group (CNBG) announced that their inactivated COVID-19 vaccine had passed phase one and two clinical trials.
The vaccine showed no "serious adverse reactions" with all volunteers generating antibodies after two doses in 28 days, the company said.